WO2010110631A3 - Benzopyran derivatives, pharmaceutically acceptable salts thereof, method for preparing same, and pharmaceutical composition for preventing or treating inflammatory diseases containing same as an active ingredient - Google Patents

Benzopyran derivatives, pharmaceutically acceptable salts thereof, method for preparing same, and pharmaceutical composition for preventing or treating inflammatory diseases containing same as an active ingredient Download PDF

Info

Publication number
WO2010110631A3
WO2010110631A3 PCT/KR2010/001887 KR2010001887W WO2010110631A3 WO 2010110631 A3 WO2010110631 A3 WO 2010110631A3 KR 2010001887 W KR2010001887 W KR 2010001887W WO 2010110631 A3 WO2010110631 A3 WO 2010110631A3
Authority
WO
WIPO (PCT)
Prior art keywords
inflammatory diseases
preventing
treating inflammatory
pharmaceutically acceptable
pharmaceutical composition
Prior art date
Application number
PCT/KR2010/001887
Other languages
French (fr)
Korean (ko)
Other versions
WO2010110631A2 (en
Inventor
이상구
이형규
안경섭
이미영
권옥경
김희성
육지은
김민석
오세량
Original Assignee
한국생명공학연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국생명공학연구원 filed Critical 한국생명공학연구원
Publication of WO2010110631A2 publication Critical patent/WO2010110631A2/en
Publication of WO2010110631A3 publication Critical patent/WO2010110631A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to benzopyran derivatives, to pharmaceutically acceptable salts thereof, to a method for preparing same, and to a pharmaceutical composition for preventing or treating inflammatory diseases containing same as an active ingredient. As the benzopyran derivatives according to the present invention exhibit the activities of inhibiting the increase of eosinophils or inhibiting the secretion of bronchial mucus in an ovalbumin-induced asthma animal model, as well as of inhibiting the production of nitrogen monoxide (NO) which causes inflammatory diseases, the derivatives may be useful as agents for preventing or treating inflammatory diseases.
PCT/KR2010/001887 2009-03-27 2010-03-26 Benzopyran derivatives, pharmaceutically acceptable salts thereof, method for preparing same, and pharmaceutical composition for preventing or treating inflammatory diseases containing same as an active ingredient WO2010110631A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2009-0026360 2009-03-27
KR1020090026360A KR101292188B1 (en) 2009-03-27 2009-03-27 Benzopyrane derivatives, pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical composition for preventing or treating inflammatroy diseases containing the same as an active ingredient

Publications (2)

Publication Number Publication Date
WO2010110631A2 WO2010110631A2 (en) 2010-09-30
WO2010110631A3 true WO2010110631A3 (en) 2011-03-17

Family

ID=42781698

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/001887 WO2010110631A2 (en) 2009-03-27 2010-03-26 Benzopyran derivatives, pharmaceutically acceptable salts thereof, method for preparing same, and pharmaceutical composition for preventing or treating inflammatory diseases containing same as an active ingredient

Country Status (2)

Country Link
KR (1) KR101292188B1 (en)
WO (1) WO2010110631A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999033821A1 (en) * 1997-12-24 1999-07-08 Allergan Sales, Inc. Benzopyran and benzothiopyran derivatives having retinoid antagonist-like activity
US7138411B2 (en) * 1997-04-21 2006-11-21 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138411B2 (en) * 1997-04-21 2006-11-21 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
WO1999033821A1 (en) * 1997-12-24 1999-07-08 Allergan Sales, Inc. Benzopyran and benzothiopyran derivatives having retinoid antagonist-like activity

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DONGLEI YU ET AL.: "Anti-AIDS Agents. 60. Substituted 3'R,4'R-Di-O-(-)-camphanoyl-2', 2'-dimethyldihydropyrano[2,3-f]chromone (DCP) Analogues as Potent Anti-HIV Agents", JOURNAL OF MEDICINAL CHEMISTRY, vol. 47, no. 16, 2004, pages 4072 - 4082 *
GENEIVE E. HENRY ET AL.: "A short synthesis of 5-methoxy-2,2- dimethyl-2H-1-benzopyran-6-propanoic acid methyl ester", TETRAHEDRON, vol. 57, no. 25, 2001, pages 5335 - 5338, XP004245634, DOI: doi:10.1016/S0040-4020(01)00456-2 *
JEFFREY T. NORTH ET AL.: "Synthesis of 6-Cyano-2,2-dimethyl-2H-l-benzopyran and Other Substituted 2,2-Dimethyl-2H-l-benzopyrans", JOURNAL OF ORGANIC CHEMISTRY, vol. 60, no. 11, 1995, pages 3397 - 3400 *
KANDASAMY SUBBURAJ ET AL.: "Microwave-Assisted Rate-Enhanced Method for the Synthesis of 2,2-Dimethyl-2H-chromenes", BULL. CHEM. SOC. JAPAN, vol. 72, no. 2, 1999, pages 259 - 263 *

Also Published As

Publication number Publication date
KR101292188B1 (en) 2013-08-02
WO2010110631A2 (en) 2010-09-30
KR20100107962A (en) 2010-10-06

Similar Documents

Publication Publication Date Title
WO2010088000A3 (en) Antifibrotic compounds and uses thereof
HK1138840A1 (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
MX2014000341A (en) Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease.
WO2011127290A3 (en) Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
WO2006120682A3 (en) Compositions and methods for treating hyperproliferative epidermal diseases
WO2010037066A3 (en) Dosage units of 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
WO2009109618A3 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1
WO2008094992A3 (en) 2-aminopyridine derivatives useful as kinase inhibitors
WO2009109616A8 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
WO2014045162A8 (en) ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-AMINE COMPOUNDS
WO2011051490A3 (en) Heterocyclic derivatives
MX2011010415A (en) Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof.
WO2011141929A3 (en) Aqueous pharmaceutical compositions of fluticasone and olopatadine
WO2009109654A8 (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1
MY165003A (en) Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative
SG10201900504XA (en) Pharmaceutical composition comprising glutarimide derivatives and use thereof in the treatment of eosinophilic diseases
WO2010090494A3 (en) Medical use of 5-benzylaminosalicylic acid derivatives or salts thereof
EP2407472A4 (en) Polyfluoroalkylphosphonic acid, method for producing same and mold-releasing agent comprising same as active ingredient
EP2583962A4 (en) Novel thiourea or urea derivative, preparation method thereof, and pharmaceutical composition for preventing or treating aids, containing same as active ingredient
MD4563C1 (en) Co-micronisation product comprising ulipristal acetate
WO2011009533A3 (en) 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl derivatives, methods for the production thereof and use thereof for treating diseases
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
WO2012024583A3 (en) Oxysterol compounds
WO2008023003A8 (en) Drug combinations for treating airway diseases
WO2012155226A8 (en) Method for producing pyrostegia venusta derivatives, pyrostegia venusta derivatives, pharmaceutical compositions and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10756386

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10756386

Country of ref document: EP

Kind code of ref document: A2